We are going to take a close look at AbbVie Inc. (NYSE: ABBV) today to get a better sense of the company and its current status, as well as the opportunity it may offer for prospective investors. Today?s focus will be a fundamental evaluation of the stock from top to bottom.

As such, let’s start with the top line: Revenue trends.

Last quarter, the company saw its overall sales move to 6.94B in total revenues. That represents an overall change in revenues, on a quarterly year/year basis of 0.07%. If we translate that into sequential terms, the company saw sales grow by 0.06% from quarter to quarter.

It?s important to closely track the top line data. Theres no better way to measure the end markets reception of a companys products. But no one truly wins without bottom line success, which is what we need to look at next.

AbbVie Inc. NYSE: ABBV is intriguing when broken down to its core data. The cost of selling goods last quarter was 1.57B, yielding a gross basic income of 5.37B. For shareholders, given the total diluted outstanding shares of 1.6B, this means overall earnings per share of 1.19 . Note, this compares with a consensus analyst forecast of 1.43 in earnings per share for its next fiscal quarterly report.

Given that data, we now turn to a more thorough glance across analyst expectations for the company going forward.

At present, analysts hold a consensus average recommendation of Overweight. This is based on a total of 21 analysts. While we dont suggest taking analyst recommendations at face value plans for action in a portfolio, we do think it is important to note where consensus is on a stock to understand what basic assumptions are perhaps already discounted into the market pricing of shares of the stock.

As far as price targets, analysts currently have an average target on shares at 80.18. In addition, if we turn to next year, we see estimates of a fiscal year forecast to bring about 6.51 in total earnings per share. On a median price to earnings ratio basis, that outlook adds up to a valuation of 13.47 times earnings.

At this point, we’ve taken a thorough look at this company from top to bottom and gotten a sense of what analysts are expecting. But underneath it all, when push comes to shove, companies make it through tough times on balance sheet strength. With that in mind, we should take a look under the hood here.

As the reader is no doubt aware, for any company, balance sheet health sits at the heart of the companys capacity to stand up to the demands and obligations incurred by normal and contingency operations, which in turn lies at the core of a company’s ability to retain the faith of investors in the marketplace. For (NYSE: ABBV), the company presently holds about 6.09B in cash in the coffers. That cash is balanced against 3.42B about in total current liabilities.

Its important to consider both a static and dynamic picture, particularly where debt levels are concerned. This means we need to take into account any trends. In this case, the companys debt has been growing . The company also has 66.99B in total assets, balanced by 60.99B in total liabilities, which suggests where this story might go under adverse economic or financial conditions.

As far as cash flows, the company saw a free cash flow last quarter of 1.88B, representing a quarterly net change in cash of 1.35B.On a net operating level, the company saw about 2B in cash flow.

We will update the interesting story of AbbVie Inc. NYSE: ABBV as new events transpire.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE